- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01885845
Excellent BRASSS-V Drape™ Versus Indirect Measurement Protocol for Measurement of Postpartum Blood Loss
A Comparison of the Excellent BRASSS-V Drape™ and an Indirect Blood Measurement Protocol for the Measurement of Blood Loss During Third Stage of Vaginal Delivery
Postpartum hemorrhage is one of the most common causes of maternal mortality and serious maternal morbidity, especially in the developing world. In India, hemorrhage is a major cause of maternal mortality: A study by the Register General in 1993 showed that 23 percent of all maternal deaths in rural areas were caused by hemorrhage (Sibley, 2005).
The measurement of postpartum blood loss and identification of postpartum hemorrhage are important measures in efforts to prevent and treat postpartum hemorrhage. In recent years, researchers have employed several different methods to measure blood loss in hospital and community-based birth settings. Although research has demonstrated that these laboratory measures are more accurate then visual estimation techniques, no studies have explicitly documented the systematic differences (if any) among different collection modalities. Moreover, only a few of these studies have correlated measured blood loss with changes in hemoglobin levels experienced between the antepartum and postpartum period. The aim of this study is to compare variations in the measurement of blood loss obtained using two popular measurement methods: the Excellent BRASSS-V Drape™ and a modified version of the blood collection method developed by the World Health Organization (WHO).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Postpartum hemorrhage is one of the most common causes of maternal mortality and serious maternal morbidity, especially in the developing world. In India, hemorrhage is a major cause of maternal mortality: A study by the Register General in 1993 showed that 23 percent of all maternal deaths in rural areas were caused by hemorrhage (Sibley, 2005).
The measurement of postpartum blood loss and identification of postpartum hemorrhage are important measures in efforts to prevent and treat postpartum hemorrhage. However, visual estimation of postpartum hemorrhage often leads to underestimation of blood loss and subsequent delays in the seeking or provision of appropriate treatment. In recent years, researchers have employed several different methods to measure blood loss in hospital and community-based birth settings. Although research has demonstrated that these laboratory measures are more accurate then visual estimation techniques, no studies have explicitly documented the systematic differences (if any) among different collection modalities. Moreover, only a few of these studies have correlated measured blood loss with changes in hemoglobin levels experienced between the antepartum and postpartum period. The aim of this study is to compare variations in the measurement of blood loss obtained using two popular measurement methods: the Excellent BRASSS-V Drape™ and a modified version of the blood collection method developed by the World Health Organization (WHO).
We propose a randomized prospective study to compare the measurement of blood loss during the third stage of labor with two different methods: the modified WHO blood measurement protocol and the Excellent BRASSS-V Drape™. Upon admission in the labor ward, study staff will approach all delivering women about participation in the study and seek informed consent. Blood loss will be measured for all consenting women with vaginal deliveries.
Women who agree to participate will be randomized to one of two blood collection techniques: a modified version of the WHO blood measurement protocol or the Excellent BRASSS-V Drape™. Blood loss will be measured from immediately after delivery and cord clamping for a period of at least one hour or until active bleeding stops. The blood loss will then be quantified by the study staff and recorded on the study form. Women will receive the facility's standard care for the management of the third stage of labor and, if applicable, treatment of PPH.
Measures of postpartum hemoglobin levels will be taken at admission for delivery and twenty-four hours post-delivery for a randomly selected sub-set of study participants. Besides the measurement of blood loss and the regular measurement of hemoglobin for a sub-sample of participants, there will be no change to the hospital's standard procedures for labor and delivery.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Pune, India
- KEM Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
• Vaginal birth
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: BRASSS-V drape
Immediately after delivery and cord clamping, blood measurement will begin.
The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs.
Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
|
Immediately after delivery and cord clamping, blood measurement will begin.
The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs.
Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
|
|
Sperimentale: Indirect weight method
Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped. After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml. |
Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped. After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Mean blood loss
Lasso di tempo: after delivery to when active bleeding has stopped or at least one hour
|
after delivery to when active bleeding has stopped or at least one hour
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Hillary Bracken, PhD, Gynuity Health Projects
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2.4.7
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Emorragia postpartum
-
Halic UniversityNon ancora reclutamentoDolore lombopelvico postpartum | Mal di schiena postpartum | Dolore della Cintura Pelvica PostpartumTurchia (Türkiye)
-
Northwestern UniversityReclutamento
-
The University of Texas Health Science Center,...CompletatoPostpartum | Turni di mediciStati Uniti
-
Assistance Publique Hopitaux De MarseilleSconosciuto
-
Selcuk UniversitySelcuk University Scientific Research Projects UnitReclutamento
-
Cairo UniversityReclutamento
-
FHI 360Ghana Health Services; Ministry of Health, ZambiaCompletatoPeriodo postpartumGhana, Zambia
-
London School of Hygiene and Tropical MedicineDepartment for International Development, United Kingdom; Economic and Social... e altri collaboratoriCompletatoPeriodo postpartumBurkina Faso
-
University of North Carolina, Chapel HillSociety of Family PlanningCompletatoContraccezione postpartumStati Uniti
Prove cliniche su Excellent BRASSS-V Drape™.
-
Solventum US LLCReclutamentoSostituzione dell'artroplastica, ginocchio | Artroplastica totale dell'ancaStati Uniti
-
Vectorious Medical Technologies Ltd.Reclutamento
-
Technical University of MunichCompletatoConfronto del numero di infezioni del sito chirurgico | Copertura della parete addominale nelle laparotomie con una protezione del bordo della ferita addominale 3M™ Steri-Drape™ approvata e tessuto standard | TamponiGermania
-
Vectorious Medical Technologies Ltd.Reclutamento
-
Vectorious Medical Technologies Ltd.Reclutamento
-
Vectorious Medical Technologies Ltd.Horizon 2020 - European CommissionAttivo, non reclutante
-
Sino Medical Sciences Technology Inc.CompletatoDisfunsione dell'arteria coronaria | Angina pectoris stabile | Angina pectoris instabileCina
-
Abbott Medical DevicesCompletatoArresto cardiacoGermania
-
Engeneic Pty LimitedJohns Hopkins UniversityCompletatoGlioblastoma | Astrocitoma, grado IVStati Uniti
-
Abbott Medical DevicesCompletatoIschemia miocardica | Disfunsione dell'arteria coronaria | Arteriosclerosi coronarica | Trombosi dello stent | Malattia vascolare | Stenosi coronarica | Occlusione coronarica totale | Restenosi dell'arteria coronaricaFrancia, Italia, Norvegia, Cina, Spagna, Germania, Regno Unito, Svizzera, Israele, Danimarca, Belgio, Austria, Polonia, Australia, Portogallo, Argentina, Brasile, Ungheria, Lettonia, Olanda, India, Grecia, Malaysia, Federazione... e altro ancora